Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule
Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years
FSME IMMUN NEW Follow-Up to Study 205 in Children Aged 6 to 16 Years
FSME IMMUN NEW Follow-Up to Study 199 in Children Aged 1 to 6 Years
Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children
Postencephalitic Symptoms After Tick Borne Encephalitis
Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
Dose-Finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.
Dose-Finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.
Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years
Influence of Persistent CMV-infection on Immune Senescence
† Indicates status has not been verified in more than two years